Table 3.
Laboratory examinations during the treatment period (means ± SD).
| Placebo group |
Lithium group |
|||
|---|---|---|---|---|
| Pre-treatment | Post-treatment | Pre-treatment | Post-treatment | |
| Liver function | ||||
| Alanine transaminase (U/l) | 16.9 ± 8.9 | 17.8 ± 7.3 | 18.5 ± 11.1 | 17.8 ± 9.9 |
| Aspartate transaminase (U/l) | 26.4 ± 4.3 | 27.2 ± 8.6 | 29.8 ± 11.3 | 25.8 ± 5.4 |
| γ-glutamyltransferase (U/l) | 12.8 ± 3.4 | 12.5 ± 3.3 | 13.1 ± 5.2 | 16.8 ± 12.74 |
| Alkaline phosphatase (U/l) | 243.1 ± 53.4 | 218.0 ± 70.6 | 221.2 ± 61.7 | 214.6 ± 68.4 |
| Total protein (g/l) | 68.7 ± 3.6 | 67.8 ± 3.1 | 69.1 ± 4.3 | 68.9 ± 4.6 |
| Albumin (g/l) | 46.4 ± 2.7 | 46.8 ± 3.9 | 46.4 ± 2.9 | 47.2 ± 3.3 |
| Globulin (g/l) | 22.3 ± 3.1 | 21.0 ± 3.2 | 22.7 ± 3.2 | 21.7 ± 2.7 |
| Total bilirubin (μmol/L) | 9.4 ± 2.6 | 9.3 ± 3.7 | 9.5 ± 3.8 | 9.2 ± 2.6 |
| Direct bilirubin (μmol/L) | 2.0 ± 0.8 | 2.3 ± 0.8 | 2.3 ± 1.1 | 2.2 ± 0.7 |
| Indirect bilirubin (μmol/L) | 7.5 ± 2.4 | 7.0 ± 2.9 | 7.8 ± 4.6 | 7.0 ± 2.1 |
| Renal function | ||||
| Urea (mmol/L) | 4.5 ± 1.0 | 3.5 ± 0.5 | 4.6 ± 1.2 | 4.4 ± 1.3 |
| Creatinine (μmol/L) | 31.7 ± 6.9 | 29.2 ± 3.8 | 31.0 ± 7.5 | 33.0 ± 7.7 |
| Uric acid (μmol/L) | 228.9 ± 83.2 | 241.0 ± 103.6 | 242.0 ± 75.6 | 259.6 ± 74.6 |
| Thyroid function | ||||
| Free T3 (pmol/L) | 5.8 ± 0.5 | 5.8 ± 0.4 | 5.8 ± 0.8 | 5.9 ± 0.5 |
| Free T4 (pmol/L) | 15.1 ± 2.7 | 15.1 ± 2.5 | 15.6 ± 2.2 | 16.3 ± 1.9 |
| Thyroid stimulating hormone (mIU/L) | 2.8 ± 1.9 | 2.6 ± 1.6 | 2.8 ± 1.6 | 3.4 ± 1.7 |
| Routine blood tests | ||||
| White blood cells (109/L) | 6.7 ± 1.5 | 8.8 ± 1.5 | 7.9 ± 3.6 | 7.6 ± 3.2 |
| Red blood cells (1012/L) | 4.6 ± 0.4 | 4.7 ± 0.4 | 4.4 ± 0.5 | 4.6 ± 0.4 |
| Hemoglobin (g/L) | 125.3 ± 8.8 | 129.5 ± 13.4 | 122.0 ± 10.7 | 124.1 ± 12.6 |
| Platelets (109/L) | 186.9 ± 19.8 | 190.0 ± 21.6 | 189.4 ± 25.8 | 193.5 ± 29.9 |
There were no significant differences for any of the parameters between the two groups before and after treatment.